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INTERAKSI SISTEM RENIN-ANGIOTENSIN DAN SIMPATETIK 
DALAM KEADAAN HIPERTENSI DA.t~ KEGAGALAN JANTUNG 
ABSTRAK 
Klonidin (2-[(2, 6-diklorofenil)-amino]-2-midazolin), merendahkan tekanan darah 
melalui tindakannya ke atas a.radrenoseptor tmtuk mengurangkan aliran luar 
simpatetik. Klonidin telah dittmj11kkan memptmyai kesan hipotensif berpusat dan 
dimediasi oleh .tindakan terus ke atas otak, membawa kepada penurunan ton simpatet:ik. 
Perindopril menunmkan tekanan darah dengan menghalang aktiviti enzim pemJkar 
angiotensin di dalam subjek manusia dan haiwan. Angiotensin II adalah satu 
vasokonstriktor periferal yang poten di mana ianya mengaruh rembesan aldosteron oleh 
adrenal korteks dan menyediakan tindakbalas negatifke atas !ernbesan renin. 
Objektif kajian ini ialah unttlk menilai peranan drug bertindak pusat, klonidin 
dan perencat enzim penukar angiotensin II, perindopril di dalam perubahan respon 
presor kepada pelbagai agonis adrenergik dan angiotensin II eksogenus di dalarn tikus 
normal dan hipertensif dengan atau tanpa kegagalan janttmg. Basil kajian ini 
berkem1mgkinan boleh dig1makan nnttlk mengenalpasti interaksi antara sistem renin-
angiotensin dan simpatetik di dalam keadaan penyakit-penyakit ini. 
Kegagalan jantung diamhkan dengan kombinasi rawatan kafein (40 mg/kg) dan 
isoprenalina (5 mg/kg) selama tujuh hari. Haiwan-haiwan diagihkan kepada Japan 
kmnpulan. Empat kumpulan pertama terdiri daripada tikus Wistar, tikus Wistar dengan 
kegagalan jantung, SHR dan SHR dengan kegagalan jantllllg, diberi klonidin (50 
!J.g/kg). Kumpnlan kedua terdiri daripada tikus Wistar, tikus Wistar dengan kegagalan 
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jantung, SHR dan SHR dengan kegagalan janumg, diberi perindopril (0.2 mglkg). 
klonidin dan perindopril diberi secara oral selama 6 hari. Kumpulan-kurnpulan kawalan 
diberi samaada salin biasa atau tween 80 mengikut kaedali yang sama Di dalam kajian 
akut,. haiwan-haiwan ini diberi anastesia (natrium pentobarbiton, 60 mglkg i.p), dan 
trakeotomi dilakukan. Arteri karotid kiri dikanulat untllk pengukuran tekanan darah, 
vena jugular kiri dikanulat unulk membenarkan infhsi berterusan anastesia ( 12.5 
mglkglh) dan untuk pemberian dos bolus agonis, noradrenalina (NA) (200, 400 dan 800 
nglkg), fenilephrina (PE) (2, 4 and 8Jtglkg), metoksamina (ME) (2, 4 dan 8Jtglkg) and 
angiotensin II (Ang II) (5, 10 dan 20 nglkg). 
Perubahan tekanan darah disebabkan oleh agonis-agonis ini direkod sebagai 
respon pressor. Data, mean ± s.e.m dibandingkan dengan kaedah ANOV A dua-hala 
diik:uti dengan ujian pos-hok Duncan dengan tahap signiflkan 5%. Keputusan-keputusan 
yang diperolehi menunjukkan NA dan PE menghasilkan respon pressor yang dos 
dependen di dalam semua kumpulan dirawat dengan klonidin. Respon-respon pressor 
ini berbeza dengan signifikan berbanding dengan kumpulan kawalan masing-masing 
untuk tikus Wistar, tilms Wistar dengan kegagalan janumg dan SHR 
Walaubagaimanapun, tiada pembahan signifikan di dalam respon pressor diumjllkkan 
oleh kumpulan SHR dengan kegagalan janumg bila diband.ingkan dengan kurnpulan 
kawalan. ME menghasilkan respon pressor yang dos dependen di dalam tikus Wistar 
dan SHR yang dirawat dengan perindopril dan respon-respon ini adalah berbeza secara 
signifikan bila dibandingkan dengan kumpulan kawalan, manakala, tiada perbezaan 
signifikan di dalam respon yang diperhatikan di dalam Wistar dengan kegagalan jantung 
dan SHR dengan kegagalan janttmg bila mana ME diberikan. 
Berdasarkan kepun1san yang diperolehi di dalam kajian ini, boleh disimpulkan di dalam 
tikus Wistar yang normal dan tikus Wistar dengan kegagalan jantung, pemberian 
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klonidin tidak memberi perubahan ke atas respon pressor dengan pemberian Ang II 
tetapi perubahan signifikan terhadap agonis adrenergik diperhatikan. Ini menlmjukkan 
bahawa penghalangan sistem simpatetik periferal oleh klonidin tidak memberi kesan ke 
atas sistem renin-angiotensin di dalarn tikus Wistar yang normal dan tikus Wistar 
dengan kegagalan janumg. Di dalam SHR dan SHR dengan kegagalan jantung yang 
dirawat dengan klonidin, respon pressor kepada pemberian Ang II diubah tetapi tidak 
kepada agonis adrenergik. Penemuan ini memmjukkan berketmmgkinan wujudnya satu 
interaksi kompleks di antara sistem simpatetik dan renin-angiotensin di dalam 
kumpulan-kumpulan haiwan ini. Di dalam kumpulan tikus Wistar normal dan tikus 
Wistar den"gan kegagalan janumg, pemberian perindopril menyebabkan perubahan 
pressor respon kepada pemberian Ang II dan agonis adrenergik. Ini menunj1.1kkan 
sistem simpatetik periferal oleh perindopril dikompromasi sistem renin-angiotensin di 
dalam tilms Wistar normal dan tikus Wistar dengan kegagalan janumg. Namun, di 
dalam SHR dan SHR dengan kegagalan janumg yang dirawat dengan perindopril. tiada 
perubahan signiflkan dalam respon pressor kepada agonis adrenergik dan Ang II 
diperhatikan. Kesemua penemuan dari kajian ini secara kolektifuya mencadangkan 
berkemungkinan wujudnya sat1.1 interaksi antara sistem renin-angiotensin dan simpatetik 
di dalam proses kawalatl.lf tekanan darah di dalam model-model haiwan yang digtmakan 
di dalam kajian ini. 
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ABSTRACT 
Clonidine (2-[(2, 6-dichlorophenyl)-amino]-2-imidazoline), reduces blood pressure via 
its action on a.2-adrenoceptors to decrease sympathetic outflow. Clonidine has been 
demonstrated to exert its hypotensive effect centrally and is mediated by direct action 
on the brain, leading to a decrease of sympathetic tone. Perindopril lowers blood 
pressure by inhibiting ACE activity in human subjects and animals. Angiotensin II is a 
potent peripheral vasoconstrictor which stimulates aldosterone secretion by the adrenal 
cortex and provides negative feedback on renin secretion. 
The objective of this study was to assess the role of centrally acting drug, 
clonidine and an angiotensin II converting enzyme inhibitor, perindopril in the 
modification of pressor responses to various exogenous adrenergic agonists and 
angiotensin II in normal and hypertensive rats with or without heart failure. The 
outcome of this study could then be used to establish the interaction of the renin-
angiotensin and sympathetic systems in these disease states. 
Heart failure was induced by combined treatment of caffeine (40 mg/kg) and 
isoprenaline ( 5mg/kg) for seven days. The animals were divided into eight groups. The 
first four groups composing of the Wistar rats, heart failure Wistar rats, SHR and heart 
failure SHR, these groups were given clonidine (50 f.!g/kg). The second four groups 
consisted of the Wistar rats, heart failure Wistar rats, SHR, and SHR with heart failure 
and given perindopril (0.2 mg/kg). Clonidine and perindopril were administered orally 
for six days. Control groups received either normal saline or tween 80 in the same 
manner respectively. In acute studies, the animals were anaesthetized (&,mium 
pentobarbitone, 60 mg/kg i.p), and a tracheostomy done. The left carotid artery was 
cannulated for measurement of blood pressure, the right jugular vein was cannulated for 
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a continuous infusion of anaesthesia .. ( 12.5 mg!kglh) and to inject bolus doses of agonists 
i.e, NA (200, 400 and 800 ng!kg), PE (2, 4 and 8j.ig/kg), ME (2, 4 and 8J.lg/kg) and Ang 
II ( 5, 10 and 20 ng!kg). 
The changes in blood pressure due to the agonists were recorded as pressor 
responses. Data, means ± s.e.m were compared with two way ANOV A followed by 
Dtmcan' s post -hoc test with the significance level of 5%. The results obtained indicated 
that the NA and PE produced pressor responses that were dose dependent in all groups 
of animal treated with clonidine. These pressor responses were significantly different as 
compared to their respective control groups in Wistar rats, heart failure Wistar rats and 
SHR. However no significant changes in the pressor :responses were seen in the heart 
failure SHR group as compared to control group. Methoxamine produced dose 
dependent pressor responses in Wistar rats and heart failure Wistar rats treated with 
clonidine. The pressor responses were significantly different as compared to their 
control groups. No significant changes in the pressor responses were observed when the 
ME was administered in SHR and heart failure SHR group as compared to control 
groups. 
Angiotensin II produced dose dependent pressor responses in the SHR and heart 
failure SHR treated with clonidine. These pressor responses were significantly different 
as compared to control groups. No significant difference in the pressor responses was 
observed when the Ang II was administered in the Wistar rats and heart failure Wistar 
rats treated with donidine as compared to their control groups. Noradrena]jne, PE and 
Ang Il produced dose dependent pressor responses in all groups of animals treated with 
perindopril, which were si1:,Yflificantly different as compared to their respective control 
groups in Wistar rats and heart failure Wistar rats. However, no significant changes in 
the pressor responses were seen in SHR and SHR with heart failure as compared to 
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control groups. Methoxamine produced dose dependent pressor responses in Wistar rats 
and SHR rats treated with perindopril and these responses were significantly different as 
compared to control groups where as no significant changes in the responses were 
observed in the heart failure Wistar and SHR heart failure rats when ME was 
administered. 
Based on the results obtained in this study, it is concluded that in the normal 
Wistar rats and heart failure Wistar rats, the administratjon of clonidine did not cause 
any pressor response changes to the administration of Ang II but significant change to 
the adrenergic agonist was seen. This indicates that the blockade of the peripheral 
sympathetic system by clonidine did not compromise the RAS in normal Wistar rats and 
heart failure Wistar rats. In the SHR and heart failure SHR treated with clonidine, the 
pressor responses to the administration of Ang II were altered but no significant changes 
to the adrenergic agonist were seen. This finding may indicate that a complex 
interaction between the sympathetic system and RAS in these groups of animal. In the 
normal Wistar rats and heart failure Wistar rats, the administration of perindopril caused 
pressor response changes to the administration of Ang II and adrenergic agonists. This 
indicated that the blockade of peripheral sympathetic system by perindopril 
compromised the RAS in normal Wistar rats and heart failure Wistar rats. However,, in 
the SHR and heart failure SHR treated with perindopril. no significant changes in the 
pressor responses to the adrenergic agonist and Ang II were seen. The fmdings from this 
study collectively suggested that there is a possible interaction between the RAS and the 
sympathetic system in the regulation of blood pressure in the animals used in this study. 
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1.1 Hypertension 
CHAPTER ONE 
INTRODUCTION 
Hypertension is defined as an ·elevation of arterial blood pressure above an 
arbitrarily defined normal value (Beard et a/., 1992; Guidieral et a/., 1996 and Helge et 
al., 2001 ). Blood pressure is the product of peripheral vascular resistance and cardiac 
output. An. increase in cardiac output or peripheral resistance results in an increase in 
blood pressure. However, if one of these factors increases whilst the other decreases, the 
blood pressure may not be affected. 
The level of resting arterial pressure varies consirl:erably from person to person, 
and ~ese variations may be related to factors such as age, sex, temperature and 
emotional state (Folkow and Svanberg, 1993; Mulvany eta/., 1991 and Guyton, 1990). 
An arbitrary level for hypertension is frequently set at 140/90 mm Hg (systolic/ 
diastolic), and those with arterial pressures consistently higher than these at rest are 
considered to be hypertensive. Obviously, there are degrees of hypertension, from very 
mild to very severe. In the latter, pressure may rise to 240/140 mm Hg, or even higher. 
In some cases, only the systolic or the diastolic pressure is elevated, although in most 
cases both are increased but not necessarily equally (Bianchi and Ferrari, 1992 and 
Creigh et al., 1992). 
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In more than two-thirds of patients with hypertension, a specific disturbance in a 
particular organ system cannot be fmmd as the cause of elevated blood pressure. These 
patients are said to have primary or essential hypertension. In the remaining cases a 
definite cause can be established. These patients have non-essential, or secondary 
hypertension. The most common diseases in which there is an associated hypertension 
are those involving the heart, central nervous system, endocrine system, and kidney 
(Olson, 1998 and Helge eta!., 2001). 
1.1.1 Cardiovascular hypertension 
Cardiovascular hypertension occurs when systemic arterial pressure is elevated 
by an increase either in cardiac output or peripheral resistance (Cowley, 1992). High 
output states, such as hyperthyroidism will increase pressure lmless accompanied by 
peripheral vasodilatation. Usually, only moderate increases are seen due to high 
outputs. An increased cardiac output may also occu:i- in adrenal disease. More 
commonly, the vessels lose their dispensability with age, which tends to increase 
systolic pressure. If the smaller vessels are involved, mean pressure may be markedly 
increased, as seen in generalized arteriosclerosis. High pressure itself, if maintained for 
a sufficient time (weeks to months), may cause a permanent change in the blood vessels 
that will prevent the return of peripheral resistance to normal even though the primary 
cause of the hypertension has been cured or removed (Olson, 1998). 
1.1.2 Neurogenic hypertension 
In neurogenic hypertension there is an increase in sympathetic tone resulting 
from a disturbance of cerebral blood flow. This may occur during cerebral ischemia, in 
cases of hemorrhage within the cranium, or related to a space--occupying mass, e.g., a 
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brain tumor within the cranial vault. Blood pressure will become elevated in an attempt 
to maintain cerebral flow. Thus a raised blood pressure after a head injury is often a 
sign of intracranial bleeding. In some cases the carotid sinus or aortic arch 
baroreceptors are unable to respond to changes in blood pressure. This might occur, for 
example, with tramnatic injury to the carotid sinus nerves, arteriosclerosis changes in 
the wall of the internal carotid, or a tmnor in the baroreceptor areas (Dampey, 1994 and 
Shaohua et al., 2002). 
1.1.3 Endocrine hypertension 
Endocrine hypertension refers to several diseases of the endocrine system 
associated with an elevation of blood pressure. Disease of the adrenal medulla, which 
secretes the catecholamines adrenaline (AD) and noradrenaline (NA), may result in 
excessive production of these hormones. Since NA is the major transmitter for the SNS, 
and AD has similar actions in larger doses, an increase in vasomotor tone and 
myocardial force will occur. This occurs, for example, in the presence of a 
pheochromocytoma, an adrenal medullary tmnor that secretes excessive quantities of 
catecholamines, thereby causing an increase in peripheral resistance and cardiac output. 
Removal of the tmnor is usually curative. Tmnors of the adrenal cortex associated with 
increased production of corticosteroids may also cause high blood pressure. One such 
tumor produces aldosterone in large ammmts; which acts on the kidney to cause sodium 
and water reten6on results in an increase in blood volume. In Cushing's syndrome, 
glucocorticoids are produced in excessive quantities by the adrenal cortex. They 
apparently also influence the kidney to retain fluid and result in mild to moderate 
hypertension (Retting et al., 1990). 
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1.1.4 Renal hypertension 
Damage to the kidney itself may result in renal hypertension. Reduction of renal 
blood flow by arterial occlusion or renal artery compression consistently produces 
hypertension regardless of whether or not renal nerve fibers are present. The kidney 
produces a htuneral agent known as renin. an enzyme that acts on a circulating plasma 
protein to produce the polypeptide angiotensine I (Ang I). Angiotensine I is inactive 
but may be readily converted to an active from angiotensine II ( Ang II), Ang II that 
produces widespread arterial vasoconstriction and resultant hypertension. It may also 
stimulate the production, release, or both. of aldosterone from the adrenal cortex. The 
amount of reriin released may be greatly increased in conditions of renal ischemia. 
Kidney disease is therefore an important cause of hypertension. Removal of the 
diseased kidney, in cases in which only one kidney is involved, may reverse the 
hypertension (Lifton, 1996). 
1.1.5 Essential hypertension 
Thus far we have discussed disease states known to produce hypertension. In 
most cases of hypertension, however, no abnormality in cerebral blood flow, cardiac 
output, renal function, or the endocrine system can be demonstrated (essential 
hypertensjon). The reasons are unclear and the mechanisms involved not well 
understood, but a munber of theories have been advanced to explain such cases (Levy et 
al., 19%). 
One of these postulates swelling of the smooth muscle cells that make up the 
arterioles due to an increase in sodium and water content. The consequent 
encroachment of these swollen cells on the hun en of the arteriole results in an increase 
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in arteriolar resistance. The basic disorder producing the swollen cells is unknown. 
However, it may not be the fimdamental process and may only reflect disease elsewhere 
for example in the kidney. An increase in blood vohune oftell occurs also for reasons 
that are not apparent. Some investigators have postulated that the baroreceptors are reset 
to a higher-than-nonnallevel. Alternatively, the control centers in the CNS could be set 
to a higher level. The sensitivity of the carotid sinus might be reduced by 
arteriosclerosis changes in the wall of the carotid artery (Manunta et al., 2001). 
1.2 Neural control in blood pressure 
There are two important contributors to the control of blood pressure, the 
sympathetic nervous system (SNS) and the renin-angiotensin system (RAS) (Borchard 
2001; Rupp and Jager, 2001). The autonomic nervous system is important in regulating 
cardiovascular homeostasis as it modifies both cardiac output and the diameter of 
resistance vessels. Blood vessels, however, are innervated almost exclusively by fibers 
of the SNS, which regulate vasomotor tone. Increased SNS activity results in increased 
vasomotor tone and, therefore, is causally related to the development and maintenance 
of high blood pressure (DiBona eta!., 1996). 
The RAS has become established as an endocrine system that plays important 
roles in the physiological regulation of cardiovascular, renal, and endocrine ftmctions. 
It contributes to the development and persistence of various forms of hypertension 
(Cody et al., 1983). Activation of this system leads to the formation of renin in the 
kidney, which converts angiotensinogen to the inactive peptide, Ang I. Ang I is then 
converted by angiotensm converting enzyme (ACE) to Ang II a potent vasoconstrictor 
which also stimulates aldosterone secretion and tluid retention (Rupp and Jager, 2001 ). 
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Phannacological interventions that inhibit the RAS have been proven to be efficient 
antihypertensive and, more recently, have been shown to be beneficial in congestive 
heart failure (Rupp and Jager, 2001 ). The RAS is often considered to exert its effect on 
blood pressl.tre in an independent manner. It is now clear, however, that extensive 
interactions occur between the RAS and other blood pressure control system, in 
particular the SNS (Reid, 1992). 
The SNS controls the process by which Ang II is produced through the release 
of renin from the kidneys. As the rate of renin release by the kidneys is cmcial for the 
formation of Ang II, the SNS is a key determinant of circulating Ang II levels. 
Circulating Ang II itself then interacts with the SNS at various sites and appears to 
amplify sympathetic activity. It may act on the brain to increase sympathetic outflow, 
on the sympathetic ganglia and adrenal medulla to increase catecholamine release, and 
at presynaptic sympathetic nerve endings to facilitate sympathetic neurotransmission 
through an enhanced NA reiease (De Jonge eta/., 1984~ Reid, 1992 and Rupp and 
Jager., 2001 ). 
1.3 Adrenergic receptors 
Adrenergic receptors (adrenoceptors) mediate the central and peripheral actions 
of primary sympathetic neurotransmitter, NA and the primary adrenal medullary 
hormone (and central transmitter), adrenaline. Adrenoceptors are tbtmd in most ofthe 
peripheral tissues and on many neural tissues within the central nervous system. These 
adrenoceptors mediate a variety of fimctions such as blood pressure, myocardial 
contractile rate and force, airway reactivity, and an array of metabolic ftmctions. Several 
types of neuronal varicosities also have prej1.mctional (presynaptic) adrenoceptors 
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serving as auto or heteroreceptors that inhibit or modify nerve-evoked release of several 
neurotransmitters (Bylund eta!., 1994). 
There are multiple, closely related adrenoceptor subtypes, although their exact 
munber and the appropriate mode of grouping into major fiunilies is still controversial. 
Generally, current knowledge classifies the adrenoceptors into three major subtypes, 
called <11, a2 and ~-adrenoceptors (Byhmd eta/., 1994). 
These subclassifications are based on several functional, molecular and 
radio ligand binding studies after several considerations. Firstly, that the different major 
types of adrenoceptors affinity for selective dmgs are 3 to 4 orders of magnitude (i.e. a~, 
a2 and f3), and the affinity ratio for each major subtype is only between 10 to 100. 
Secondly, the. second-messenger responses of each major subtype is different and 
finally, that the predicted amino acid sequences of tlie adrenoceptors are more 
consistent with three rather than two major type (Byhmd et a!., 1992). These three 
subtypes are further subclassified in to several subtype, a1A. am, am and a.2A, U:2B, azc 
and am and f3I, f3z and .f33 (Bylund et a!., 1994; Cooper et a!., 19% and Zhong and 
Minneman. 1999). 
1.3.1 nt-adrenoceptors 
u1-adrenoceptors exist as heterogenous family. More than a decade age, 
pharmacological studies indicated the existence of a 1A and a1B-adrenoceptors (Han et 
al., 1987; and Minneman et a!., 1988). The development of adrenoceptor researches, 
based on pharmacological and molecular studies have indicated that these cloned 
subtypes correspond to native a1A, alB and am-adrenoceptor subtypes (Ford eta!., 1994; 
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Hieble et al., 1995 and Byhmd et al., 1998). Functionally, these receptors were 
characterized by their high affinity for prazosin and low affinity for yohimbine (Bytmd 
eta!., 1994). 
ll1-adrenoceptor subtypes are widely expressed in different neonatal and adult rat 
tissues. High levels of IliA and CI10-adrenoceptors were detected in brain and heart 
whereas similar levels of U1B-adrenoceptors in liver and heart of neonatal rats by 
immunoreactive mechanism. In adult rat tissues, a 1A-adrenoceptors protein were most 
marked in the brain, intermediate in heart, aorta, liver, vas deferens and adrenals, and 
minimal in the kidney and prostate as compared to other tissues. The expression of um-
adrenoceptors· was higher in the brain and heart but the expression of CI10-adrenoceptors 
in brain was most prominent (Shen, et al., 2000). a1-adrenoceptor subtypes are 
localized in different parts of the cell. a 1A-adrenoceptor subtypes tor example, are 
localized in perinuclear fashion, whereas llm-adrenoceptor subtype was detected 
throughout the entire border of the cell (Hirasawa et al., 1997). Further studies on the 
vascular smooth muscle did not indicate that the CI1P. and am-adrenoceptor subtypes 
were defined on the cell but that the a 1 -adrenoceptor subtypes were fmmd in the 
intercellular compartment (Hrometz et al .. 1999). 
All 1I1-adrenoceptor subtypes are activated by the sympathetic neurotransmitters, 
noradrenaline, adrenaline, even though none of these catecholamines exhibit selective 
affinity to any of these adrenoceptor subtypes. CI1-adrenoceptor mediated responses are 
blocked by prazosin and show a low affinity for selective aradrenoceptor antagonists 
such as yohimbine (Morrow and Greese 1986 and Byhmd et a!., 1994). IIJ-
adrenoceptor-induced vasoconstrictions appear to be caused both by release of 
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intracellular calcium and by the transmembranous influx of extracellular calcimn 
(Caufin and Malik, 1984~ Byh.md et al., 1994; and Zhong and Minneman, 1999). 
a1-adrenoceptors involve rapid processes such as sequestration and slower 
processes such as receptor downregulation (Garcia-Sainz, 1993 and Cotecchia eta!., 
1995). The slower downregulation of these receptors may be related to the 
pathophysiological processes which occur in disease states such as cardiac failure and 
chronic renal failure (Packer, 1992a). According to Dong and Han (1995), am-
adrenoceptor mediated vasoconstriction is easier to be desensitized, while a 1A-
adrenoceptor mediated constriction is easier to be hypersensitized. Furthermore, both 
a1A and am-adrenoceptor subtypes are functionally upregulated in spontaneously 
hypertensive rat (SHR) muscle vascular bed. This may provide some clue for the 
possible role of a 1-adrenoceptor subtypes in maintenance of elevated blood pressure (Y e 
and Colquho1.m, 1998). F1.mctional expression of am-adrenoceptor in the rat resistance 
vessels increase with age; a1A but not am or am-adrenoceptors, which seem to 
predominate in immature animals. This represents the first evidence that age-related 
changes in functional c.:tt-adrenoceptor subtypes occur in the systemic vasculature in vivo 
(DeMey 1997; DeOliveira eta/., 1998 and Ibarra et al., 1999). In addition, all the three 
receptor subtypes increased with age in the brain cortex, whereas the density of am-
adrenoceptor increased in the heart but decreased in the liver. Furthermore, 111A-and 
lltn-adrenoceptor popldation in liver, kidney and heart of rats were not affected by age 
(Shen et al., 2000). 
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1.3.2 a:z-adrenoceptors 
The a.2-adrenoceptors can be pre and postjtmctional. Some of the prejunctional 
are neuroinhibitory in their action (Byhmd, 1988; Akers et a!., ·1991 and Oriowo et a!., 
1991 ). Prejunctional inhibitory a.radrenoceptors are predominantly of the a.2A-
adrenoceptors subtype. Furthennore, a.2C-adrenoceptors may also occur prejunctionally 
(Docherty, 1998). a.2-a:drenoceptors play an important role in mediating the sympathetic 
nervous system effects on blood pressure. a.radrenoceptor can be phannacologically 
divided to a.2A. a.2B, and a.2c-adrenoceptors, all of which mediate contractile responses 
(Cooper eta!., 19%; Docherty, 1998 and Zhong and Minneman, 1999). They are 
activated to variable extents by catecholamines, exerting different effects depending of 
their localization (Irena et al., 2000). The a.2A-adrenoceptor subtype are located in the 
central nervous system and concentrated in the brainstem (Tavares eta!., 19%) which is 
known to be the center of cardiovascular control, and is responsible for the tonic 
regulation of the sympathetic nervous system. The nm-adrenoceptors, on the other hand 
are thought to be the only subtype located in the vascular smooth cell of the arterial 
wall, and having a role in the vasoconstriction action (Link eta!., 1996; MacMiiian et 
a!., 19% and Altman eta!., 1999). 
1.4 Specific sympathomimetic drugs 
Drugs which partially or completely mimic the effect of sympathetic nerve 
stimulation or adrenal medullary discharge are termed as sympathomimetics. A wide 
variety of dmgs have sympathomimetic activity and they may be classified into dmgs 
which act: 
1- Directly on adrenoceptors e.g. the catecholamines, adrenaline (AD) and 
noradrenaline . 
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2- Indirectly, causing release of noradrenaline from the adrenergic nerve ending e.g 
amphetamine. 
3- By both mechanisms e.g. dopamine. 
1.4.1 Catecholamines 
The brain contains separate neuronal systems that utilize three different 
catecholamines i.e dopamine, NA, and AD. Each system is anatomically distinct and 
serves separate, but with similar ftmctional roles within their fields of innervations. 
Much of the original mapping was performed in rodent brains (Hokfelt et al., 1976, 
1977; Foote, 1997 and Lewis, 1997). Catecholamines induce direct vasoconstriction 
mediated by postsynaptic a-adrenergic receptors of both a1 and a2 type (Irena et al., 
2000). 
1.4.1.1 Noradrenaline (NA) 
In contrast to AD, NA acts almost exclusively on a-adrenoceptors, although it is 
less potent at these receptors sites than adrenaline. Infusions of all doses ofNA increase 
both systolic and diastolic arterial pressure by vasoconstriction of arteriolar and venous 
smooth muscle. Despite some stimulatory effects on cardiac contraction, the intense 
vasoconstriction leads either to no change or to a decrease in cardiac output at the cost 
of increased myocardial oxygen demand. In high dosage the lmiversal vasopressor 
effect reduces renal blood flow and glomemlar filtration rate (Aitkenhead and Smith, 
1998). 
Noradrenaline effects on the ~ 1 receptors in the heart are with a similar potency 
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as on a-receptors. In contrast it has relatively little effect on ~2 receptors. 
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Consequently, NA increases peripheral resistance and both diastolic and systolic blood 
pressure. Compensatory vagal reflexes tend to overcome the direct positive 
chronotropic effect of NA but the positive intropic effects on the heart are maintained 
(Bertam and Katzung,. 1995). The cardiovascular effect of an intravenous infusion of 
NA is that the systolic and diastolic pressure and usually pulse pressure are increased. 
Cardiac output is unchanged or decreased, and total peripheral resistance is raised 
(Ruffolo and Hieble 1999). Compensatory vagal reflex activity slows the heart, 
overcoming a direct cardioaccelerator action and stroke volwne is increased. The 
peripheral vascular resistance increases in most vascular beds, and blood flow is 
reduced to kidneys. Noradrenaline constricts mesenteric vessels and reduces 
splanchnic and hepatic blood flow. Coronary flow is usually increased probably owing 
both indirectly induced coronary dilation as with epinephrine, and to elevated blood 
pressure (Grossman eta/., 1993). 
1.4.2 Phenylephrine ( PE) 
Phenylephrine is a synthetic a.1-selective agonist (Swnmers, 1984 and 
Nishimatsu et al., 1999), but having a better affinity for the a.1A and a.m as compared to 
a.m-adrenoceptors (Goetz et al., 1995). It activates f3-adrenergic receptors only at much 
higher concentrations. Phenylephrine causes marked arterial vasoconstriction during 
intravenous infusion. Phenylephrine also is used as a nasal decongestant and as a 
mydriatic in various ophthalmic formulations (Bertam and Katztmg, 1995). 
1.4.3 Methoxamine(ME) 
Methoxamine has been used as a prototype of a.-adrenoceptor agonists m 
phannacological experiments as-- well as in a clinical setting. While it has been 
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established that ME acts preferentially on a-adrenoceptors, methoxamine has additional 
effects on f3-adrenoceptors and a direct, non specific action on ion channels, and thus, it 
has stimulatory as well as inhibitory effects on cardiac contraction (Scholz, 1980 and 
Endoh, 1982). In the rabbit ventricular myocardium, ME stimulates the hydrolysis of 
phosphoinositide with an efficacy identical to that ofPE, whereas the potency of ME is 
approximately ten times lower than that of PE (Yang and Endoh, 1994 ). It is also 
remarkable that, in contrast to PE, ME elicits a much less pronounced positive inotropic 
effect upon cumulative administration than upon single administration. Moreover, ME 
inhibits the positive inotropic effect of PE over a range of concentrations at which it 
causes the acceleration of the hydrolysis of phosphoinositide (Yang and Endoh, 1994 ). 
Methoxamine is a predominantly directly acting a1. receptor agonist or, more 
specifically, by a1A-adrenoceptors (Huang et a/., 1996). It may cause a prolonged 
increase in blood pressure due to vasoconstriction. It also causes a vagally mediated 
bradycardia. Methoxamine is available for parenteral use, but clinical applications are 
rare and limited to hypotensive states (Kuo, 1998). 
1.5 Renin-angiotensin system (RAS) 
The renin-angiotensin system is an important participant in both the short-and 
long-terms regulation of arterial blood pressure (Dzau 1987; Jin eta/., 1987; Seyer et 
a!., 1991 ~ Mickaelle, 1993~ Inagami, 1994 and Gary eta!., 2001 ). Factors that decrease 
arterial blood pressure, such as a decrease in eff~<;tjve blood volume (caused by 
diuretics, blood loss, congestive heart failure, liver cirrhosis, or nephritic syndrome) or 
reduction in total peripheral resistance (caused by for example vasodilators), activates 
renin release from the kidneys (Blaufarb and Sannenblick, 1996). 
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Renin is synthesized and stored in an inactive fonn called prorenm m the 
juxtaglomerular cells of kidneys, which are modified smooth muscle cells located in the 
walls of the afferent arterioles immediately proximal to the glomeruli (Everet et a!., 
1990). When the arterial pressure falls, intrinsic reactions in the kidneys themselves 
causes many of these prorenin molecules to split and release renin. Most of the renin 
enters the blood and leaves the kidneys to circulate throughout the entire blood stream, 
although a small amount remains in the local fluids ofthe kidney (Gary et al., 2001 and 
Dinh, 2001). 
Renin is an enzyme, not a vasoactive substance itself it acts enzymatically on 
another plasma protein, a globulin called renin substrate (or angiotensinogen ) to release 
a 10 -amino acid peptide, Ang I. Ang I has mild vasoconstrictor properties but not 
enough to cause significant functional changes in circulatory function. The renin 
persists in the blood for 30 minutes to an hour and continues to cause formation of Ang 
I. During few seconds after formation of the Ang I, two additional amino acids are 
split from it to form the 8-amino acid peptide Ang II. This conversion occurs almost 
entirely in the small vessels of the lungs, catalyzed by the ACE that is present in the 
endothelium of the lung vessels (Dinh, 2001). 
1.5.1 Actions of angiotensin II (Ang II) 
Angiotensin II acts at several sites in the body, including vascular smooth 
muscle, adrenal cortex, kidney, and brain (Goodfriend et al., 19%); actions the RAS 
plays a key role in the regulation of fluid and electrolyte balance and arterial blood 
pressure. Ang II receptors are located on the plasma membrane of target cells 
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throughout the body. Two distinct receptor subtypes, termed AT1 and AT2, have been 
identified (Goodfriend et al., 1996). 
Ang II is a potent pressor agent, considerably more potent than NA. The pressor 
response to Ang II is rapid in onset (10- 15 seconds) and sustained during long-term 
infusions of the peptide: A large component of the pressor response to intravenous Ang 
II is due to direct contraction of arteriolar smooth, muscle mediated by AT 1 receptors. 
However, Ang II also increases blood pressure through actions on the brain and 
autonomic nervous system. In particular, it acts centrally to increase sympathetic 
outflow and peripherally to facilitate sympathetic transmission by increasing the release 
and reducing the reuptake of NE at adrenergic nerve terminals (Reid, 1992). It also has 
a less important direct positive inotropic action on the heart. The pressor response to 
angiotensin is usually accompanied by little or no reflex bradycardia because the 
peptide acts on the brain to reset the baroreceptor reflex control of heart rate to a higher 
pressure (Reid, 1992). Ang II acts on the zona g1omerulosa of the adrenal cortex to 
stimulate aldosterone biosynthesis. Aldosterone in turn increases sodium reabsorption 
in the distal tubule and acts on the kidney to cause renal vasoconstriction, increase 
proximal tubular sodium reabsorption, and inhibit the secretion of renin (Timmermans 
eta!., 1993). 
1.5.2 Function of the renin-angiotensin system 
As mentioned earlier the RAS plays a major role in regulating arterial blood 
pressure over both the short and long tenn (Dzau, 1987; Jin eta!., 1987; Seyer eta!., 
1991; Mickaelle eta/., 1993; Inagami, 1994 and Gary et al., 2001). Modest increases in 
plasma concentration of Ang II acutely increase blood pressure. On molar basis, Ang II 
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is approximately 40 times more potent than NA in this regard. Where Ang II is injected 
interavenously, systemic blood pressure begins to rise within seconds, rapidly reaches 
maximum, and returns to normal within minutes (Gary et al., 2001). 
This rapid pressor response to Ang II is due to a swift increase in total peripheral 
resistance, a response that helps maintain arterial blood pressure in the face of an acute 
hypotensive challenge (e.g. blood loss, vasodilation}. Although Ang II directly 
increases cardiac contractility (via opening voltage-gated ca2+ channels in cardiac 
myocytes} and indirectly increases heart rate (via facilitation of sympathetic tone) 
enhanced noradrenergic neurotransmission and adrenal catecholamine release. The 
rapid increase in arterial blood pressure activates a baroreceptor reflex that decreases 
sympathetic tone and increases vagal tone. Thus, Ang II may increase, or not change 
cardiac contractility, heart rate, and cardiac output, depending on the physiological 
state. Therefore, changes in cardiac output contribute little if at all to the rapid pressor 
response induced by Ang II (Ferguson and Washburn, 1998). 
Angiotensin II also causes a slow pressor response that helps stabilize arterial 
blood pressure over the long term. A continuous infusion of initially suppressor doses 
of Ang II gradually increases arterial blood pressure, with the maximum effect requiring 
days to achieve (Brown et a!., 1981). Angiotensin II induces the stimulation of 
endothelin-I (Laursen et al., 1997) and super oxide anion (Rajagopalan et al., 1997) 
production mediates, in part, the slow pressor response. In addition, to buffering short 
and long-term changes in arterial blood pressure, Ang II significantly alters the 
morphology of the cardiovascular system i.e., it causes hypertrophy of vascular and. 
cardiac cells (Fink, 1997). 
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1.5.3 AngotensiiKonverting enzyme inhibitors 
1.5.3.1 Perindopril 
Perindopril is a long acting angiotensin converting enzyme (ACE) inhibitor 
which displays similar effect as captopril (Mancini, 1998). It prevents the conversion of 
Ang I to Ang II by inhibition of angiotensin-converting enzyme. This results in reduced 
peripheral vascular resistance and decreased aldosterone production. It also reduces 
pre~load and after~Ioad in congestive heart failure, and reduces tissue concentration of 
Ang II leading to arterial and venous dilation (Flather eta/., 2000 and Mancini 2000). 
Oral administration of perindopril produces dose dependent inhibition of plasma 
ACE activity in normotensive and hypertensive animals (Laubie et al., 1984; Moursi et 
a/., 1986 and Lo et al., 1990}healthy human subjects (Lees & Reid eta/., 1987; Waeber 
et al., 1989}, hypertensive patients (Plouin eta/., 1988} and'patients with congestive 
heart failure (Thuillez eta/., 1990). As consequence of this ACE inhibition, a decrease 
in plasma Ang II levels occurs, as well as increases in plasma renin activity and plasma 
Ang I levels mediated by a negative feedback. Furthermore, a somewhat variable but 
frequent decrease in plasma aldosterone} levels it also observed. Further evidence of 
inhibition of ACE following oral perindopril administration is provided by blockade of 
the pressor response to exogenously administered Ang I in animals (Laubie et al., 1984; 
DiNicola.ntonio and Doyle, 1986 and Doyle et al., 1986) and humans (Waeber et al., 
1989}. 
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1.6 Congestive heart failure 
1.6.1 Autonomic innervation of the heart 
The medulla, located in the brainstem, receives sensory input from different 
systemic and central receptors (e.g., baroreceptors and chemoreceptors) as well as 
signals from other brain re~ons (e.g., cortex and hypothalamus). Autonomic outflow 
from the brainstem is divided principally into sympathetic and parasympathetic (vagal) 
branches. Efferent fibers of these autonomic nerves travel to the heart and blood vessels 
where they modulate activity of these target organs. 
The heart is innervated by both vagal and sympathetic fibers. The right vagus 
nerve primarily innervates the sinoatrial node (SA node) while the left vagus innervates 
the atrioventricular node (AV node). However, there can be significant overlap in the 
anatomical distribution. Atrial muscle is also innervated by vagal efferents where as the 
ventricular myocardimn is only sparsely innervated by vagal efferents. The sympathetic 
efferent nerves are present throughout the atria (especially in SA node) and ventricles, 
and in the conduction system of the heart (Richard et a/., 1993). 
1.6.2 Congestive heart failure 
Congestive heart failure is defined as a pathophysiologic state in which an 
abnormality of cardiac function is responsible for the failure of the heart to pmnp blood 
at a rate to commensurate with the requiren1ents of the metabolizing tissues during 
stress or exercise (Folkow and Svanberg, 1993 and Herny and Wilson, 2001). 
Congestive heart failure occurs when the cardiac output is inadequate to provide the · 
oxygen needed by the body. Although it is believed that the primary defect in heart 
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failure resides in the excitation-contraction coupling machinery of the heart, this clinical 
condition also involves many other processes and organs, including the baroreceptor 
reflex, the sympathetic nervous system, the kidneys, the RAS "and vasopressin (Bertam 
and Katzung, 1995). The primary signs and symptom of all types of congestive heart 
failure includes tachycardia, decreased exercise tolerance and shortness of breath, 
peripheral and pulmonary edema, and cardiomegaly. Decreased exercise tolerance with 
rapid muscular fatigue is the major direct consequence of diminished cardiac output. 
The other manifestations result from the attempts by the body to compensate for the 
intrinsic cardiac defect (Bertarn and Katzung, 1995). 
1.6.3 Sympathetic activation in heart failure 
The sympathetic nervous system is activated in heart failure, via low and high 
pressure baroreceptors, as an early compensatory mechanism which provides inotropic 
support and maintains cardiac output. Chronic sympathetic activation, however, has 
deleterious effects, causing a further deterioration in cardiac function (Grossman 
199land McDonagh et a/., 1998). The earliest increase in sympathetic activity is 
detected in the heart, and this seems to precede the increase in sympathetic outflow to 
skeletal muscle and the kidneys that is present in advanced heart failure. Sustained 
sympathetic stimulation activates the RAS system and other neurohormones, leading to 
increased venous and arterial tone (and greater preload and afterload respectively), 
increased plasma NA concentrations, progressive retention of salt and water, and 
oedema. Excessive sympathetic activity is also associated with cardiac myocyte 
apoptosis, hypertrophy, and focal myocardial necrosis (Packer, 1992a and Manolis et 
a/.,1995). 
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In the long term, the ability of the myocardium to respond to chronic high 
concentrations of catecholamines is attenuated by a down regulation in f3 receptors 
although this may be associated with baroreceptor dysftmction and a ftrrther increase in 
sympathetic activity. Indeed, abnormalities of baroreceptor function are well 
documented in chronic heart failure, along with reduced parasympathetic tone, leading 
to abnormal autonomic modulation of the sinus node. Moreover, a reduction in heart 
rate variability has consistently been observed in chronic heart failure as a result of 
predominantly sympathetic and reduced vagal modulation of the sinus node, which may 
be a prognostic marker in patients with chronic heart failure (Grossman,l991 and 
McDonagh ei al., 1998). Sympathetic activation during heart failure serves as an 
important compensatory mechanism, but is also a precipitating factor in worsening heart 
failure. A common finding in heart failure patients and experimental models is that the 
sympathetic adrenergic branch of the autonomic nervous system is activated and this 
results in cardiac stimulation, peripheral vascular constriction and activation of the 
RAS. 
1.6.3.1 Cardiac stimulation 
Sympathetic activation of the heart causes an increase in heart rate and inotropy 
via the release ofNA acting primarily upon f31-adrenoceptors. The increase in inotropy 
by sympathetic activation however, may not be sufficient to restore normal intropy 
particularly in ventricles having systolic dysftmction (Cohn eta!., 1984 and Kaye et al., 
1995). Sympathetic activation has other important effects which can be deleterious, 
including ventricular hypertrophy, enhanced arrhythmogenesis, and molecular and 
biochemical changes that lead to ftrrther dysftmction over time (Prakash and 
Deedwania, 1997). Therefore, although sympathetic activation may play. some 
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compensatory role in the failing heart, there is considerable evidence that it actually 
exacerbates heart failure. For this reason, the use of beta-blockers in some forms of 
heart failure has been gaining in popularity because of their p10ven efficacy (Richard et 
al., 1993 and Jackson et al., 2000). 
1.6.3.2 Peripheral Vascular Constriction 
Arterial and venous vessels are richly innervated by sympathetic nerves and 
activation of these nerves causes release ofNA that binds primarily to postjunctional ar 
adrenoceptors causing smooth muscle activation and vasoconstriction. Arterial 
vasoconstriction increases systemic vascular resistance which raises arterial pressure. In 
heart failure, particularly when cardiac output is significantly reduced, arterial 
vasoconstriction helps to maintain arterial pressure (Prakash and Deedwania, 1997). 
The increased systemic vascular resistance, however, contributes to an increase 
in the afterload of the heart which can further depress systolic~ function. Peripheral 
vasoconstriction, particularly in the smaller arterioles, limits muscle perfusion during 
exercise thereby contributing to the decrease in exercise capacity. Contractions of 
venous vessels enhance venous return and preload which helps to maintain stroke 
volume through the Frank-Starling mechanism. The resulting increase in venous 
pressure, however, can lead to peripheral edema (Prakash and Deedwania, 1997). 
Peripheral vasoconstriction caused by enhanced sympathetic activation can be both 
beneficial and deleterious in heart failure. The deleterious aspects of sympathetic 
activation can be offset by using arterial and venous vasodilator drugs. This therapeutic 
approach is very important in the treatment of heart failure (Richard eta!., 1993 ). 
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The vascular endothelium has an important role in the regulation of vascular tone, 
i'L ~ releasing relaxing and contracting factors tmder basal conditions or during exercise. The 
f 
increased peripheral resistance in patients with chronic bean failure is related to the 
alterations in autonomic control, including heightened sympathetic tone, activation of 
the RAS system, increased endothelin concentrations, and impaired release of 
endothelium derived relaxing factor (or nitric oxide). There is emerging evidence that 
impaired endothelial ftmction in chronic heart failure may be improved with exercise 
training and drug treatment, such as ACE inhibitors (Jackson eta/., 2000). 
1.6.3.3 Activation of the renin-angiotensin system 
Enhanced sympathetic outflow to the kidneys causes an increase in renin release. 
This is mediated by ~adrenoceptors in the kidney. Plasma renin activity, therefore, is 
often elevated in heart failure patients, in part, because of increased sympathetic 
activity. Increased renin release causes increased formation of Ang II that has several 
important effects on volume regulation, blood pressure regulation, and cardiac function 
and pathology (Colucci and Bratmwald, 2000). 
Stimulation of renin angiotensin system leads to increased concentratjons of 
renin, plasma Ang Il, and aldosterone. Angiotensin II is a potent vasoconstrictor of the 
renal (efferent arterioles) and systemic circulation, where it stimulates release of NA 
from sympathetic nerve terminals, inhibits vagal tone, and promotes the release of 
aldosterone. This leads to the retention of sodium and water and the increased excretion 
of potassium. In addition, Ang II has important effects on cardiac myocytes and may 
contribute to the endothelial dysfimction that is observed in chronic heart failure 
(Jackson et al., 2000). 
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1.6.4 Pathophysiology of heart failure 
Congestive heart failure is a syndrome with multiple causes that involve the 
right ventricle, the left ventricle, or both. Cardiac output in congestive heart failure is 
usually below the normal ranges. The causes of the decreased cardiac output that 
eventually leads to heart failure can be roughly divided into two groups. In patients 
with conditions such as myocardial infarction or some forms of valvular disease, the 
ventricle is distorted and less able to contract efficiently (systolic dysfimction) and the 
end systolic volwne is increased. In patients with hypertension and some funns of 
cardiomyopathy, diastolic compliance is decreased and end-diastolic volume is 
increased (diastolic dysfimction) (Grossman, 1991 and Ho et al., 1993). 
The most important intrinsic compensatory mechanism is myocardial 
hypertrophy. This increase in muscle mass helps to maintain cardiac performance in the 
face of adverse effects such as pressure or volume overload, loss of fimctional tissue 
(myocardial infarction), or decrease in cardiac contractility. However, after an initial 
beneficial effect, hypertrophy can lead to ischemic changes, impairment of diastolic 
filling, and alterations ventricular geometry (Bertam and Katzung, 1995). Briefly, 
systolic dysfimction results from loss of intrinsic inotropy (contractility}, most likely 
due to alterations in signal transduction mechanisms responsible for regulating inotropy. 
Global systolic dysfunction results from a loss of intrinsic inotropy (contractility), most 
likely due to alterations in signal transduction mechanisms responsible for regulating 
inotropy. Global systolic dysfunction can also result from the loss of viable contracting 
muscle as following acute myocardial infarction. Diastolic dysfimction refers to the 
diastolic properties of the ventricle and occurs when the ventricle becomes less 
compliant, which impairs ventricular filling. Both systolic and diastolic dysfimctions 
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result in higher ventricular end-diastolic pressure which serves as a compensatory 
mechanism by utilizing the Frank-Starling mechanism to augment stokes volume. The 
ventricle dilates as preload pressures increase in order to recruit the Frank- Starling 
mechanism in an attempt to maintain nonnal stroke volumes (William eta/., 1998) 
Most commonly, a primary change in cardiac dysfunction precipitates changes 
in vascular function, blood volume, and neurohtunoral status. To a point, changes in 
these non---arrdiac factors serve as compensatory mechanisms to help maintain cardiac 
output (primarily by the Frank-Starling mechanism) and arterial blood pressure (by 
systemic vasoConstriction). However, change in non-cardiac factors can also precipitate 
or aggravate cardiac dysfunction. Therefore, some of the most effective treatments for 
chronic heart failure involve modulating non-cardiac factors such as arterial and venous 
pressures by administering vasodilator and diuretic drugs (Richard eta/., 1993). 
1.6.4.1 Neurohumoral changes 
Neurohumoral responses in heart failure include activation of sympathetic nerve 
and the renin-angiotensin system, and increased release of antidiuretic hormone 
(vasopressin) and artial natriuretic peptide. The baroreceptor reflex appears to be at 
"rest" with a lower sensitivity to arterial pressure, in patients with heart failure. Hance 
baroreceptor sensory input to the vasomotor center is reduced and even at normal 
pressure sympathetic outflow is increased whereas parasympathetic outflow is 
decreased (Packer, 1992b and Jackson et al., 2000). Increased sympathetic outflow 
causes tachycardia, increased cardiac contractility, and increased vascular tone. 
Increased arterial tone results in increased afterload and decreased ejection fraction, 
cardiac output, and renal perfusion. Elevation of venous tone results in increased 
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